Back to all peptides

Retatrutide

A once-weekly GLP-1/GIP/glucagon receptor triple agonist in late-stage trials for obesity—next-gen metabolic peptide drug.

Updated July 26, 2026 · By The Peptide Dex — Gut Editorial

Reading a prescription or supplement label

On a prescription or label?

Retatrutide

GLP-1 medicines and gut peptides have distinct names—brand names, generics, and research codes.

Pharmacokinetic snapshot

Reference values from published sources—not prescribing or dosing advice. Cosmetic INCI peptides do not belong here; injectable and prescription contexts only.

Half-life: ~6 days
Typical dose range: 1–12 mg
Common frequency: Weekly in trials (investigational)

Source: PubMed retatrutide

Structure (cute edition)

Simplified amino acid chain for Retatrutide

This peptide is a short chain of about 4 amino acids—think of it as a tiny protein necklace on your label.

INCI: Retatrutide · ~4 amino acids in our simplified view

FDA label data

Sourced from OpenFDA drug labels (public domain). Not medical advice.

Brand names: Esokalli Slimming microcrystalline patch

Manufacturer: Guangzhou Yixin Cross-border E-commerce Co., Ltd.

Indications

Uses To support weight management To improve glycemic control in adults with type 2 diabetes mellitus Provides long-acting sustained-release delivery via soluble microneedle patch

Warnings

Warnings For external use only

Research & public records

Counts and links from public databases (PubMed, ClinicalTrials.gov, Wikidata, NIH drug nomenclature). Educational only — not medical advice.

Knowledge base: chemical compound and experimental weight-loss drug that targets three appetite-related hormones — Wikipedia

PubMed: 152 indexed papers (search PubMed)

Retatrutide fact check: Has a man died after taking the unapproved weight loss jab? · BMJ (Clinical research ed.)
Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis. · BMJ (Clinical research ed.)
Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus: a network meta-analysis based on clinical trials. · Frontiers in pharmacology
Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats. · Behavioural brain research
Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials. · High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension
GLP-1 Agonists in Adolescent Obesity: A Narrative Review of Single, Dual, and Triple Agonists. · Diabetes, metabolic syndrome and obesity : targets and therapy
Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians. · Annals of internal medicine
Retatrutide: Triple acting jab for type 2 diabetes lowers blood sugar and boosts weight loss, trial reports. · BMJ (Clinical research ed.)

Clinical trials: 111 studies on ClinicalTrials.gov (view search)

ChEMBL: RETATRUTIDE · max phase 3.0

DailyMed labels: 10 SPLs

What brands say it does

Retatrutide activates three incretin-related pathways, producing large weight loss in phase 2 trials (SURMOUNT-1 and related studies). It is not yet widely approved like semaglutide or tirzepatide. Prescription-only when approved; compounding or research sourcing carries the same risks as other unapproved GLP-1 mimics.